Adamed hopes to conquer Slovak market with Amlozek

Amlozek, the drug it wants to export appeared on the Polish market in 1998. It found its place among the top ten selling drugs in this country as it is used by about 450,000 patients a month suffering from high blood pressure. Adamed's annual income from selling Amlozek is about zł.84 million. "Our drugs do very well on foreign markets. After amlozek's success in the Czech Republic we would hope to see comparable results in Slovakia," said the company's president Maciej Adamkiewicz adding that, "During the last two years the annual market for medicines combatting high blood pressure in Slovakia increased by almost 35%. It is now worth some EUR 150 million." Adamed's 2004 exports will amount to about zł.7 million, almost 50% more than in 2003, while its projected 2004 annual revenues are zł.158 million with an expected net profit around zł.9 million. (Parkiet, p. 7) D.W.